
Annual report 2023
added 04-16-2024
Advaxis Net Debt 2011-2026 | ADXS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Advaxis
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.42 M | -657 K | -41.6 M | -19.2 M | -32.4 M | -44.1 M | -23.9 M | -113 M | -66.5 M | -17.5 M | -20.3 M | 477 K | -118 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.42 M | -113 M | -28.9 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.38 | -1.08 % | $ 367 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
DBV Technologies S.A.
DBVT
|
-188 M | $ 20.52 | 0.79 % | $ 2.86 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.72 | 3.24 % | $ 8.95 B | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.57 | -3.48 % | $ 16.1 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Forte Biosciences
FBRX
|
-58.8 M | $ 26.92 | 1.8 % | $ 349 M | ||
|
Fennec Pharmaceuticals
FENC
|
17.7 M | $ 6.22 | -3.12 % | $ 178 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Fulcrum Therapeutics
FULC
|
-191 M | $ 7.72 | -1.4 % | $ 489 K | ||
|
Galectin Therapeutics
GALT
|
-25.6 M | $ 2.24 | -12.55 % | $ 143 M | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Gilead Sciences
GILD
|
14.7 B | $ 138.79 | -0.96 % | $ 173 B | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-3.1 M | $ 0.56 | 8.45 % | $ 521 K | ||
|
Genmab A/S
GMAB
|
-6.94 B | $ 27.26 | -1.77 % | $ 17.2 B | ||
|
Gossamer Bio
GOSS
|
-33.3 M | $ 0.32 | -7.03 % | $ 73.1 M | ||
|
Grifols, S.A.
GRFS
|
5.36 B | $ 8.02 | -2.55 % | $ 6.83 B | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
GT Biopharma
GTBP
|
-5.5 M | $ 0.41 | -7.26 % | $ 2.26 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 88.74 | -2.78 % | $ 27.2 B | ||
|
Halozyme Therapeutics
HALO
|
1.27 B | $ 63.49 | 0.64 % | $ 7.61 B | ||
|
Coherus BioSciences
CHRS
|
-85.6 M | $ 1.62 | -3.1 % | $ 190 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-5.45 M | $ 3.32 | -6.21 % | $ 224 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 318.56 | -3.57 % | $ 41.7 B | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Harmony Biosciences Holdings
HRMY
|
-608 M | $ 27.62 | -0.34 % | $ 1.59 B | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
iBio
IBIO
|
-5.89 M | $ 2.08 | 2.47 % | $ 21.8 M | ||
|
ImmuCell Corporation
ICCC
|
3.77 M | $ 6.54 | -1.06 % | $ 59 M | ||
|
InflaRx N.V.
IFRX
|
-32.3 M | $ 0.99 | 4.91 % | $ 152 M | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 4.46 | -0.45 % | $ 729 M | ||
|
Immutep Limited
IMMP
|
-17.4 M | $ 0.35 | -3.58 % | $ 1.08 B |